Page last updated: 2024-08-17

nad and Idiopathic Parkinson Disease

nad has been researched along with Idiopathic Parkinson Disease in 53 studies

Research

Studies (53)

Timeframe	Studies, this research(%)	All Research%
pre-1990	4 (7.55)	18.7374
1990's	10 (18.87)	18.2507
2000's	5 (9.43)	29.6817
2010's	20 (37.74)	24.3611
2020's	14 (26.42)	2.80

Authors

Authors	Studies
Abramov, AY; Berezhnov, AV; Dolgacheva, LP; Fedotova, EI	1
Gentry, MS; Macedo, JKA; Ostrakhovitch, EA; Quintero, JE; Song, ES; van Horne, C; Yamasaki, TR	1
Brakedal, B; Brekke, N; Craven, AR; Diab, J; Dölle, C; Eidelberg, D; Grüner, R; Haugarvoll, K; Ma, Y; Nido, GS; Peng, S; Riemer, F; Schwarzlmüller, T; Skeie, GO; Skjeie, V; Sverkeli, L; Tysnes, OB; Tzoulis, C; Varhaug, K; Ziegler, M	1
Facey, PD; Hirth, F; Kocinaj, A; Parsons, AE; Parsons, RB; Prendergast, SA; Ruiz Pulido, G	1
Fathi, M; Hajibeygi, R; Jazi, K; Klegeris, A; McElhinney, A; Sayehmiri, F; Shool, S; Sodeifian, F; Tavasol, A; Tavirani, MR; Vakili, K; Yaghoobpoor, S	1
Cartas-Cejudo, P; Fernández-Irigoyen, J; Ferrer, I; Lachén-Montes, M; Santamaría, E	1
Bhayana, S; Fox, DJ; Liu, SZ; Marcinek, DJ; Mischley, LK; Shankland, E	1
Bifulco, E; Chavali, LNM; Fladmark, KE; Frøyset, AK; Grellscheid, SN; Law, JO; Mannsåker, S; Røise, D; Yddal, I	1
Liang, Y; Meng, J; Min, D; Qin, Z; Wang, Y; Yu, J; Yu, Y	1
Diederich, NJ; Fleming, RMT; Glaab, E; Gomez-Giro, G; Jaeger, C; Koseki, H; Luo, X; Monzel, AS; Nickels, SL; Preciat, G; Robertson, G; Schwamborn, JC; Sharif, J; Zagare, A	1
Af Geijerstam, SA; Berven, H; Dölle, C; Haugarvoll, K; Kverneng, S; Sheard, E; Skeie, GO; Søgnen, M; Tzoulis, C	1
Tan, EK; Zhou, ZD	1
Barrientos, A; Bazylianska, V; Nyvltova, E; Pinkerton, M; Ruetenik, A	1
Baden, P; Deleidi, M; Pérez, MJ	1
Bohr, VA; Croteau, DL; Demarest, TG; Fang, EF; Hou, Y; Lautrup, S; Mattson, MP	1
Bobbili, DR; Brockmann, K; Bus, C; Carvajal Berrio, DA; Fitzgerald, JC; Gasser, T; Glaab, E; Hauser, AK; Krüger, R; Kübler, M; Lewin, R; Madlung, J; Martins, LM; Maurer, B; May, P; Nordheim, A; Picard, D; Riess, O; Schenke-Layland, K; Schindler, KM; Schulte, C; Schwarz, LM; Sharma, M; Vartholomaiou, E; Wüst, R; Zimprich, A	1
Chakraborty, S; Chiou, A; Karmenyan, A; Tsai, JW	1
Ebert, AD; Sison, SL	1
Baden, P; Bandmann, O; De Cicco, S; Deleidi, M; Di Napoli, G; Gasser, T; Giunta, I; Heimrich, B; Ivanyuk, D; Keatinge, M; Nestel, S; Panagiotakopoulou, V; Pruszak, J; Sanchez-Martinez, A; Schöndorf, DC; Schwarz, LK; Whitworth, AJ; Yu, C	1
Kráľová Trančíková, A; Pokusa, M	1
Greenamyre, JT; McCoy, JL; Tapias, V	1
Gu, Z; James, TD; Liu, FT; Long, YT; Ma, W; Pan, ZG; Qin, LX; Wang, J	1
Annese, T; Bonifati, V; Capitanio, N; Cocco, T; De Mari, M; Dell'aquila, C; Di Paola, M; Ferranini, E; Ferretta, A; Gaballo, A; Nico, B; Pacelli, C; Piccoli, C; Tanzarella, P	1
Chong, R; Wakade, C	1
Bubacco, L; Girotto, S; Gratton, E; Jahid, S; Plotegher, N; Stringari, C; Veronesi, M	1
Chakraborty, S; Chiou, A; Karmenyan, A; Nian, FS; Tsai, JW	1
Celardo, I; Costa, AC; Lehmann, S; Loh, SH; Martins, LM	1
Abramov, AY; Delgado-Camprubi, M; Esteras, N; Plun-Favreau, H; Soutar, MP	1
Arduini, I; Bisaglia, M; Bubacco, L; Mammi, S; Soriano, ME	1
Brown, DR; Davies, P; Moualla, D	1
Choi, WS; Palmiter, RD; Xia, Z	1
Antenor-Dorsey, JA; O'Malley, KL	1
Fernandez, E; Goldstein, DS; Martinez, PA; Strong, R; Sullivan, P; Wey, MC	1
Cai, AL; Sheline, CT; Shi, C; Zhang, W; Zhu, J	1
Caspersen, C; Jackson-Lewis, V; Naini, A; Perier, C; Przedborski, S; Ramasamy, R; Teismann, P; Tieu, K; Vila, M; Wu, DC; Yan, SD	1
Abdo, WF; Bloem, BR; De Jong, D; Hendriks, JC; Horstink, MW; Kremer, BP; Verbeek, MM	1
Kunz, WS; Wallesch, CW; Wiedemann, FR; Winkler-Stuck, K	1
Holdup, D; Liptrot, J; Phillipson, O	1
Dizdar, N; Kågedal, B; Lindvall, B	1
Lange, KW; Riederer, P; Youdim, MB	1
Birkmayer, JG; Birkmayer, W; Volc, D; Vrecko, C	1
Fukushima, T; Hojo, N; Isobe, A; Shiwaku, K; Tawara, T; Yamane, Y	1
Bennett, JP; Davis, RE; Miller, SW; Parker, WD; Parks, JK; Sheehan, JP; Swerdlow, RH; Trimmer, PA; Tuttle, JB	1
Danielczik, S; Gerstner, A; Häcker, R; Kuhn, W; Mattern, C; Müller, T; Przuntek, H; Winkel, R	1
Swerdlow, RH	1
Roskoski, R; Stokes, AH; Vrana, KE; Xu, Y	1
Antion, MD; Jaumotte, JD; Kapatos, G; Pearl, SM; Stanwood, GD; Zigmond, MJ	1
Dabbeni-Sala, F; Franceschini, D; Giusti, P; Skaper, SD	1
Birkmayer, JG; Birkmayer, W; Paletta, B; Vrecko, K	1
Birkmayer, GJ; Birkmayer, W; Mlekusch, W; Ott, E; Paletta, B; Vrecko, K	1
Birkmayer, GJ; Birkmayer, W	1
Birkmayer, W; Mentasti, M	1
Birkmayer, W	1

Reviews

7 review(s) available for nad and Idiopathic Parkinson Disease

Article	Year
Dynamic changes in metabolites of the kynurenine pathway in Alzheimer's disease, Parkinson's disease, and Huntington's disease: A systematic Review and meta-analysis. Frontiers in immunology, 2022, Volume: 13 Topics: 3-Hydroxyanthranilic Acid; Adenosine; Alzheimer Disease; Humans; Huntington Disease; Hydroxyindoleacetic Acid; Kynurenic Acid; Kynurenine; NAD; Niacinamide; Parkinson Disease; Tryptophan	2022
Oxidized nicotinamide adenine dinucleotide-dependent mitochondrial deacetylase sirtuin-3 as a potential therapeutic target of Parkinson's disease. Ageing research reviews, 2020, Volume: 62 Topics: alpha-Synuclein; Humans; Mitochondria; NAD; Parkinson Disease; Sirtuin 3	2020
NAD Trends in molecular medicine, 2017, Volume: 23, Issue:10 Topics: Aging; Alzheimer Disease; Animals; Cardiovascular Diseases; Energy Metabolism; Humans; Muscular Atrophy; NAD; Parkinson Disease	2017
A novel treatment target for Parkinson's disease. Journal of the neurological sciences, 2014, Dec-15, Volume: 347, Issue:1-2 Topics: Aged; Dopamine; Female; Humans; Male; Middle Aged; NAD; Neuroprotective Agents; Niacin; Nicotinic Agonists; Parkinson Disease; Receptors, G-Protein-Coupled; Receptors, Nicotinic; Up-Regulation	2014
Recent advances in pharmacological therapy of Parkinson's disease. Advances in neurology, 1993, Volume: 60 Topics: Antiparkinson Agents; Dopamine Agents; Droxidopa; Excitatory Amino Acid Antagonists; Glutamic Acid; Humans; Levodopa; NAD; Neurologic Examination; Parkinson Disease; Receptors, Dopamine	1993
Is NADH effective in the treatment of Parkinson's disease? Drugs & aging, 1998, Volume: 13, Issue:4 Topics: Antiparkinson Agents; Humans; NAD; Parkinson Disease; Treatment Outcome	1998
The importance of monoamine metabolism for the pathology of the extrapyramidal system. Journal of neuro-visceral relations, 1969, Volume: 31 Topics: Aged; Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Brain; Catechol Oxidase; Catecholamines; Chorea; Dihydroxyphenylalanine; Dopamine; Humans; Kinetics; Methyltyrosines; Middle Aged; NAD; Parkinson Disease; Rats; Tritium; Tyrosine	1969

Trials

4 trial(s) available for nad and Idiopathic Parkinson Disease

Article	Year
The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease. Cell metabolism, 2022, 03-01, Volume: 34, Issue:3 Topics: Dietary Supplements; Humans; NAD; Niacinamide; Parkinson Disease; Pyridinium Compounds	2022
NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson's disease. Nature communications, 2023, Nov-28, Volume: 14, Issue:1 Topics: Double-Blind Method; Humans; NAD; Niacinamide; Parkinson Disease; Pyridinium Compounds	2023
Treatment of Parkinson's disease with NADH. Acta neurologica Scandinavica, 1994, Volume: 90, Issue:5 Topics: Disability Evaluation; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Humans; Infusions, Intravenous; Injections, Intramuscular; NAD; Neurologic Examination; Parkinson Disease; Pilot Projects	1994
Parenteral application of NADH in Parkinson's disease: clinical improvement partially due to stimulation of endogenous levodopa biosynthesis. Journal of neural transmission (Vienna, Austria : 1996), 1996, Volume: 103, Issue:10 Topics: Adult; Aged; Antiparkinson Agents; Biological Availability; Dihydropteridine Reductase; Enzyme Activation; Female; Humans; Infusions, Intravenous; Levodopa; Male; Middle Aged; NAD; Nerve Tissue Proteins; Parkinson Disease; Pilot Projects; Prospective Studies; Severity of Illness Index; Tyrosine 3-Monooxygenase	1996

Other Studies

42 other study(ies) available for nad and Idiopathic Parkinson Disease

Article	Year
Lactate and Pyruvate Activate Autophagy and Mitophagy that Protect Cells in Toxic Model of Parkinson's Disease. Molecular neurobiology, 2022, Volume: 59, Issue:1 Topics: Animals; Astrocytes; Autophagy; Cell Line, Tumor; Cell Survival; Humans; Lactic Acid; Membrane Potential, Mitochondrial; Mitochondria; Mitophagy; NAD; Neurons; Parkinson Disease; Pyruvic Acid; Rats	2022
Analysis of circulating metabolites to differentiate Parkinson's disease and essential tremor. Neuroscience letters, 2022, 01-19, Volume: 769 Topics: Aged; alpha-Synuclein; Biomarkers; Diagnosis, Differential; Essential Tremor; Female; Humans; Male; Middle Aged; NAD; Nicotinamide Phosphoribosyltransferase; Parkinson Disease; Pentose Phosphate Pathway	2022
Alpha-synucleinopathy reduces NMNAT3 protein levels and neurite formation that can be rescued by targeting the NAD+ pathway. Human molecular genetics, 2022, 08-25, Volume: 31, Issue:17 Topics: alpha-Synuclein; Dopaminergic Neurons; Humans; NAD; Neurites; Neuroblastoma; Nicotinamide-Nucleotide Adenylyltransferase; Parkinson Disease; Synucleinopathies	2022
Sex-divergent effects on the NAD+-dependent deacetylase sirtuin signaling across the olfactory-entorhinal-amygdaloid axis in Alzheimer's and Parkinson's diseases. Biology of sex differences, 2023, 02-08, Volume: 14, Issue:1 Topics: Alzheimer Disease; Female; Humans; Male; NAD; Parkinson Disease; Signal Transduction; Smell	2023
ATP and NAD Nutrients, 2023, Feb-14, Volume: 15, Issue:4 Topics: Adenosine Triphosphate; Humans; NAD; Parkinson Disease; Pilot Projects; Quality of Life	2023
Progressive Motor and Non-Motor Symptoms in International journal of molecular sciences, 2023, Mar-29, Volume: 24, Issue:7 Topics: Animals; Brain; NAD; Parkinson Disease; Protein Deglycase DJ-1; Zebrafish	2023
Dysbiosis of gut microbiota inhibits NMNAT2 to promote neurobehavioral deficits and oxidative stress response in the 6-OHDA-lesioned rat model of Parkinson's disease. Journal of neuroinflammation, 2023, May-19, Volume: 20, Issue:1 Topics: Animals; Dysbiosis; Gastrointestinal Microbiome; NAD; Nicotinamide-Nucleotide Adenylyltransferase; Oxidative Stress; Oxidopamine; Parkinson Disease; Rats	2023
Omics data integration suggests a potential idiopathic Parkinson's disease signature. Communications biology, 2023, Nov-20, Volume: 6, Issue:1 Topics: Dopaminergic Neurons; Humans; Mitochondria; NAD; Neural Stem Cells; Parkinson Disease	2023
Salvage NAD+ biosynthetic pathway enzymes moonlight as molecular chaperones to protect against proteotoxicity. Human molecular genetics, 2021, 05-17, Volume: 30, Issue:8 Topics: Amino Acid Sequence; Biosynthetic Pathways; Humans; Huntington Disease; Microscopy, Fluorescence; Models, Genetic; Molecular Chaperones; NAD; Nicotinamide-Nucleotide Adenylyltransferase; Parkinson Disease; Peptides; Proteostasis; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Sequence Homology, Amino Acid; Trinucleotide Repeats	2021
Progresses in both basic research and clinical trials of NAD+ in Parkinson's disease. Mechanisms of ageing and development, 2021, Volume: 197 Topics: Aging; Animals; Clinical Trials as Topic; Energy Metabolism; Humans; NAD; Parkinson Disease	2021
Metformin reverses TRAP1 mutation-associated alterations in mitochondrial function in Parkinson's disease. Brain : a journal of neurology, 2017, Sep-01, Volume: 140, Issue:9 Topics: Adenosine Triphosphate; Apoptosis; Case-Control Studies; Cells, Cultured; Fibroblasts; High-Temperature Requirement A Serine Peptidase 2; HSP90 Heat-Shock Proteins; Humans; Membrane Potential, Mitochondrial; Metformin; Mitochondria; Mitochondrial Proteins; Mutation; NAD; Organelle Biogenesis; Oxygen Consumption; Parkinson Disease; Protein Kinases; Reactive Oxygen Species; Serine Endopeptidases	2017
Inhibitory effects of curcumin and cyclocurcumin in 1-methyl-4-phenylpyridinium (MPP Scientific reports, 2017, 12-05, Volume: 7, Issue:1 Topics: 1-Methyl-4-phenylpyridinium; Animals; Cell Differentiation; Cell Survival; Curcumin; Microscopy, Fluorescence; NAD; Nerve Growth Factor; Neuroprotective Agents; Neurotoxicity Syndromes; Parkinson Disease; PC12 Cells; Rats; Reactive Oxygen Species	2017
Decreased NAD+ in dopaminergic neurons. Aging, 2018, Apr-28, Volume: 10, Issue:4 Topics: Animals; Dopaminergic Neurons; Humans; NAD; Parkinson Disease	2018
The NAD+ Precursor Nicotinamide Riboside Rescues Mitochondrial Defects and Neuronal Loss in iPSC and Fly Models of Parkinson's Disease. Cell reports, 2018, 06-05, Volume: 23, Issue:10 Topics: Animals; Autophagy; Disease Models, Animal; Dopaminergic Neurons; Drosophila melanogaster; Endoplasmic Reticulum Stress; Glucosylceramidase; Humans; Induced Pluripotent Stem Cells; Mitochondria; Mitochondrial Dynamics; Motor Activity; NAD; Neurons; Niacinamide; Parkinson Disease; Pyridinium Compounds; Unfolded Protein Response	2018
FLIM analysis of intracellular markers associated with the development of Parkinson's disease in cellular model. Physiological research, 2018, 12-31, Volume: 67, Issue:Suppl 4 Topics: alpha-Synuclein; Biomarkers; Cell Line, Tumor; Humans; Inclusion Bodies; Intracellular Fluid; Membrane Potential, Mitochondrial; Mitochondria; NAD; Optical Imaging; Parkinson Disease	2018
Phenothiazine normalizes the NADH/NAD Redox biology, 2019, Volume: 24 Topics: Animals; Biomarkers; Cell Culture Techniques; Corpus Striatum; Dopamine; Dopaminergic Neurons; Dose-Response Relationship, Drug; Immunohistochemistry; Male; Mitochondria; Models, Biological; NAD; Neuroprotection; Neuroprotective Agents; Parkinson Disease; Phenothiazines; Rats; Rotenone; Substantia Nigra	2019
Ubiquinone-quantum dot bioconjugates for in vitro and intracellular complex I sensing. Scientific reports, 2013, Volume: 3 Topics: Biosensing Techniques; Cadmium; Electrochemical Techniques; Electron Transport; Electron Transport Complex I; Humans; Mitochondria; NAD; Oxidation-Reduction; Parkinson Disease; Quantum Dots; Respiration; Selenium; Ubiquinone; Zinc	2013
Effect of resveratrol on mitochondrial function: implications in parkin-associated familiar Parkinson's disease. Biochimica et biophysica acta, 2014, Volume: 1842, Issue:7 Topics: Adenosine Triphosphate; AMP-Activated Protein Kinases; Cells, Cultured; Female; Fibroblasts; Genetic Predisposition to Disease; Humans; Middle Aged; Mitochondria; NAD; Oxidative Stress; Oxygen Consumption; Parkinson Disease; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Resveratrol; Sirtuin 1; Stilbenes; Transcription Factors; Ubiquitin-Protein Ligases	2014
NADH fluorescence lifetime is an endogenous reporter of α-synuclein aggregation in live cells. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2015, Volume: 29, Issue:6 Topics: alpha-Synuclein; Fluorescence; HEK293 Cells; Humans; Lewy Bodies; Magnetic Resonance Spectroscopy; Microscopy, Confocal; Microscopy, Electron, Transmission; Models, Biological; NAD; Parkinson Disease; Protein Aggregates; Protein Binding; Spectrometry, Fluorescence	2015
Quantification of the Metabolic State in Cell-Model of Parkinson's Disease by Fluorescence Lifetime Imaging Microscopy. Scientific reports, 2016, Jan-13, Volume: 6 Topics: Animals; Energy Metabolism; Flavin-Adenine Dinucleotide; Metabolomics; Microscopy, Fluorescence; Models, Biological; NAD; Nerve Growth Factor; Parkinson Disease; PC12 Cells; Rats	2016
Parp mutations protect against mitochondrial dysfunction and neurodegeneration in a PARKIN model of Parkinson's disease. Cell death & disease, 2016, Mar-31, Volume: 7 Topics: Animals; Blotting, Western; Brain; Dietary Supplements; Disease Models, Animal; Dopaminergic Neurons; Drosophila; Drosophila Proteins; Genotype; Longevity; Male; Membrane Potential, Mitochondrial; Mitochondria; Mutagenesis; NAD; Niacinamide; Parkinson Disease; Poly(ADP-ribose) Polymerases; Ubiquitin-Protein Ligases	2016
Deficiency of Parkinson's disease-related gene Fbxo7 is associated with impaired mitochondrial metabolism by PARP activation. Cell death and differentiation, 2017, Volume: 24, Issue:1 Topics: Adenosine Triphosphate; Cells, Cultured; Electron Transport Complex I; F-Box Proteins; Humans; Iodoacetic Acid; Isoquinolines; Membrane Potential, Mitochondrial; Mitochondria; Mitophagy; NAD; Oxygen Consumption; Parkinson Disease; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Polymorphism, Single Nucleotide; Reactive Oxygen Species; RNA Interference; RNA, Small Interfering; Sodium Cyanide	2017
Molecular characterization of dopamine-derived quinones reactivity toward NADH and glutathione: implications for mitochondrial dysfunction in Parkinson disease. Biochimica et biophysica acta, 2010, Volume: 1802, Issue:9 Topics: Animals; Dopamine; Glutathione; Humans; In Vitro Techniques; Magnetic Resonance Spectroscopy; Mice; Mitochondria, Liver; Mitochondrial Swelling; Models, Biological; NAD; Oxidative Stress; Parkinson Disease; Quinones; Spectrophotometry, Ultraviolet	2010
Alpha-synuclein is a cellular ferrireductase. PloS one, 2011, Jan-10, Volume: 6, Issue:1 Topics: alpha-Synuclein; Cell Line; Copper; FMN Reductase; Humans; Iron; Kinetics; Lewy Body Disease; NAD; Neurons; Parkinson Disease	2011
Loss of mitochondrial complex I activity potentiates dopamine neuron death induced by microtubule dysfunction in a Parkinson's disease model. The Journal of cell biology, 2011, Mar-07, Volume: 192, Issue:5 Topics: 1-Methyl-4-phenylpyridinium; Animals; Cytoplasm; Disease Models, Animal; Dopamine; Electron Transport Complex I; Mice; Microtubules; NAD; Nerve Degeneration; Parkinson Disease; Reactive Oxygen Species; Rotenone; Substantia Nigra; Vesicular Monoamine Transport Proteins	2011
WldS but not Nmnat1 protects dopaminergic neurites from MPP+ neurotoxicity. Molecular neurodegeneration, 2012, Feb-08, Volume: 7 Topics: 1-Methyl-4-phenylpyridinium; Animals; Axons; Cells, Cultured; Dopaminergic Neurons; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Mutation; NAD; Nerve Tissue Proteins; Neurites; Neuroprotective Agents; Nicotinamide-Nucleotide Adenylyltransferase; Parkinson Disease; Wallerian Degeneration	2012
Neurodegeneration and motor dysfunction in mice lacking cytosolic and mitochondrial aldehyde dehydrogenases: implications for Parkinson's disease. PloS one, 2012, Volume: 7, Issue:2 Topics: 3,4-Dihydroxyphenylacetic Acid; Aldehyde Dehydrogenase; Animals; Body Weight; Cognition Disorders; Cytosol; Disease Models, Animal; Dopamine; Female; Genotype; Male; Mice; Mice, Transgenic; Mitochondria; NAD; Neurodegenerative Diseases; Neurons; Parkinson Disease; Time Factors; Tyrosine 3-Monooxygenase	2012
Mitochondrial inhibitor models of Huntington's disease and Parkinson's disease induce zinc accumulation and are attenuated by inhibition of zinc neurotoxicity in vitro or in vivo. Neuro-degenerative diseases, 2013, Volume: 11, Issue:1 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Carrier Proteins; Cation Transport Proteins; Cell Death; Cells, Cultured; Cerebral Cortex; Dihydroxyacetone Phosphate; Disease Models, Animal; Drug Interactions; Embryo, Mammalian; Fructose-Bisphosphatase; Humans; Huntington Disease; Male; Matrix Metalloproteinase 16; Membrane Proteins; Membrane Transport Proteins; Mental Disorders; Mice; Mice, Inbred C57BL; Mice, Neurologic Mutants; Mice, Transgenic; NAD; Neurons; Niacinamide; Nitro Compounds; Oxidopamine; Parkinson Disease; Propionates; Pyruvic Acid; Rats; Rats, Long-Evans; Tyrosine 3-Monooxygenase; Zinc	2013
D-beta-hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease. The Journal of clinical investigation, 2003, Volume: 112, Issue:6 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3-Hydroxybutyric Acid; Adenosine Triphosphate; Animals; Brain; Cell Respiration; Dopamine; Dopamine Agents; Electron Transport; Electron Transport Complex I; Humans; Hydrogen Peroxide; Hydroxybutyrate Dehydrogenase; Male; Mice; Mice, Inbred C57BL; Mitochondria; Motor Activity; NAD; NADH, NADPH Oxidoreductases; Neurons; Neuroprotective Agents; Oxidants; Oxygen; Parkinson Disease; Tyrosine 3-Monooxygenase	2003
Cerebrospinal fluid analysis differentiates multiple system atrophy from Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, 2004, Volume: 19, Issue:5 Topics: Adult; Aged; Benzamides; Brain; Diagnosis, Differential; Electromyography; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Iodine Radioisotopes; Lactic Acid; Male; Methoxyhydroxyphenylglycol; Multiple System Atrophy; NAD; Parkinson Disease; Pyrrolidines; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed	2004
Effect of coenzyme Q10 on the mitochondrial function of skin fibroblasts from Parkinson patients. Journal of the neurological sciences, 2004, May-15, Volume: 220, Issue:1-2 Topics: Adenosine Diphosphate; Adult; Aged; Amobarbital; Antioxidants; Cells, Cultured; Coenzymes; Drug Interactions; Female; Fibroblasts; Glutamic Acid; Humans; Male; Middle Aged; Mitochondria; NAD; Oxygen; Parkinson Disease; Pyruvic Acid; Skin; Ubiquinone	2004
1,2,3,4-Tetrahydro-2-methyl-4,6,7-isoquinolinetriol inhibits tyrosine hydroxylase activity in rat striatal synaptosomes. Journal of neural transmission. General section, 1994, Volume: 96, Issue:1 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biopterins; Chromatography, High Pressure Liquid; Clorgyline; Corpus Striatum; Dopamine; Isoquinolines; Monoamine Oxidase; NAD; Nerve Tissue Proteins; Nomifensine; Parkinson Disease; Rats; Selegiline; Sulpiride; Synaptosomes; Tyrosine 3-Monooxygenase	1994
Nicotinamide adenine dinucleotide (NADH)--a new therapeutic approach to Parkinson's disease. Comparison of oral and parenteral application. Acta neurologica Scandinavica. Supplementum, 1993, Volume: 146 Topics: Administration, Oral; Aged; Disability Evaluation; Dopamine; Female; Humans; Infusions, Intravenous; Male; NAD; Neurologic Examination; Parkinson Disease; Tyrosine 3-Monooxygenase	1993
Radical formation site of cerebral complex I and Parkinson's disease. Journal of neuroscience research, 1995, Oct-15, Volume: 42, Issue:3 Topics: Animals; Brain; Cattle; Electrophoresis, Polyacrylamide Gel; Hydrogen-Ion Concentration; Hydroxyl Radical; Lipid Peroxidation; Mitochondria; NAD; NAD(P)H Dehydrogenase (Quinone); Niacinamide; Paraquat; Parkinson Disease; Reactive Oxygen Species; Superoxide Dismutase; Superoxides	1995
Origin and functional consequences of the complex I defect in Parkinson's disease. Annals of neurology, 1996, Volume: 40, Issue:4 Topics: 1-Methyl-4-phenylpyridinium; Aged; Apoptosis; Cell Death; DNA, Mitochondrial; Female; Humans; Male; Middle Aged; Muscle, Skeletal; NAD; NAD(P)H Dehydrogenase (Quinone); Parkinson Disease; Point Mutation	1996
Dopamine, in the presence of tyrosinase, covalently modifies and inactivates tyrosine hydroxylase. Journal of neuroscience research, 1998, Dec-01, Volume: 54, Issue:5 Topics: Animals; Antioxidants; Chromatography, Gel; Dihydroxyphenylalanine; Dithiothreitol; Dopamine; Electrophoresis, Polyacrylamide Gel; Feedback; Glutathione; Monophenol Monooxygenase; NAD; Neoplasm Proteins; Nerve Tissue Proteins; Parkinson Disease; PC12 Cells; Plant Proteins; Precipitin Tests; Rats; Tyrosine 3-Monooxygenase	1998
Effects of NADH on dopamine release in rat striatum. Synapse (New York, N.Y.), 2000, Volume: 36, Issue:2 Topics: Animals; Antioxidants; Biopterins; Cell Culture Techniques; Dopamine; Extracellular Space; Male; NAD; Neostriatum; Parkinson Disease; Potassium Chloride; Rats; Rats, Sprague-Dawley; Time Factors	2000
Melatonin protects against 6-OHDA-induced neurotoxicity in rats: a role for mitochondrial complex I activity. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2001, Volume: 15, Issue:1 Topics: Adenosine Triphosphatases; Animals; Apomorphine; Behavior, Animal; Disease Models, Animal; Electron Transport Complex IV; Electrophoresis, Polyacrylamide Gel; Male; Melatonin; Mitochondria; Motor Activity; NAD; Neuroprotective Agents; Oxidative Phosphorylation; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Substantia Nigra	2001
The clinical benefit of NADH as stimulator of endogenous L-dopa biosynthesis in parkinsonian patients. Advances in neurology, 1990, Volume: 53 Topics: Aged; Disability Evaluation; Humans; Infusions, Intravenous; Levodopa; Middle Aged; NAD; Neurologic Examination; Parkinson Disease	1990
The coenzyme nicotinamide adenine dinucleotide (NADH) improves the disability of parkinsonian patients. Journal of neural transmission. Parkinson's disease and dementia section, 1989, Volume: 1, Issue:4 Topics: Aged; Aged, 80 and over; Homovanillic Acid; Humans; Injections, Intravenous; Middle Aged; Movement Disorders; NAD; Parkinson Disease	1989
Stimulation of endogenous L-dopa biosynthesis--a new principle for the therapy of Parkinson's disease. The clinical effect of nicotinamide adenine dinucleotide (NADH) and nicotinamide adenine dinucleotidephosphate (NADPH). Acta neurologica Scandinavica. Supplementum, 1989, Volume: 126 Topics: Adult; Aged; Aged, 80 and over; Drug Evaluation; Humans; Levodopa; Male; Middle Aged; NAD; NADP; Parkinson Disease	1989
[Further experimental studies on the catecholamine metabolism in extrapyramidal diseases (Parkinson and chorea syndromes)]. Archiv fur Psychiatrie und Nervenkrankheiten, 1967, Aug-08, Volume: 210, Issue:1 Topics: Aged; Carboxy-Lyases; Catecholamines; Chorea; Dihydroxyphenylalanine; Female; Humans; Hydrazines; Male; Middle Aged; NAD; Oxidoreductases; Parkinson Disease; Phenylalanine; Tyrosine	1967